替吉奥联合顺铂治疗晚期非小细胞肺癌的临床疗效

Clinical effect on treatment of advanced non-small cell lung cancer by tegafur gimeracil oteracil potassium capsule with cis-platinum

目的探讨替吉奥联合顺铂治疗晚期非小细胞肺癌(NSCLC)的临床疗效和安全性。方法选取2013年1月至2013年8月间收治的NSCLC患者118例,根据随机数字表法分为观察组和对照组,每组59例。对照组患者予以吉西他滨联合顺铂(GP方案)治疗,观察组患者予以替吉奥联合顺铂治疗,两组均以4周为1个周期,直至病情进展或死亡或出现不能耐受的不良反应而终止治疗。比较两组患者治疗后的临床疗效,评价无进展生存时间(PFS)与总生存时间(OS),并比较两组患者的急性与亚急性毒性反应。结果观察组患者部分缓解(PR)、客观缓解率(ORR)、疾病控制率(DCR)均高于对照组,而疾病进展(PD)低于对照组,中位PFS、中位OS均长于对照组,不良反应发生率均低于对照组,差异均有统计学意义(P<0.05)。结论替吉奥联合顺铂为治疗晚期NSCLC的临床疗效较好,患者生存时间延长,且不良反应发生率低,对晚期NSCLC的临床治疗有一定的指导和借鉴意义。

Objective To explore the clinical effect and safety of tegafur gimeracil oteracil potassium capsule with cis-platinum in the treatment of advanced non-small cell lung cancer （NSCLC）. Methods Between January 2013 and August 2013, 118 NSCLC patients were enrolled in the study, and were randomly divided into the observation group and the control group, with 59 cases in each group. The patients in the control group accepted gemcitabine with cis-platinum （GP regimen）, and the patients in the observation group accepted Tegafur Gimeracil Oteracil Potassium Capsule with cis-platinum. The clinical efficacy of two groups after treatment were compared, and progression free survival （ PFS）, overall survival （OS） and acute and subacute toxicities were evaluated. Results Partial response （PR）, objective response rate （ORR） and disease control rate （DCR） in the observation group were higher than those of the control group, while progressive disease （PD） was lower than that of the control group; median PFS, median OS were longer than those of the control group; adverse reaction incidence was lower than that of the control group （P 〈 0. 05）. Conclusion It provides a new method for treatment of advanced NSCLC by tegafur gimeracil oteracil potassium capsule with cis-platinum, and the scheme has higher clinical curative effect, also patients＇ survival time is prolonged, and has lower adverse reaction incidence, and it is better than GP scheme, so it has certain guidance to advanced NSCLC＇ s clinical treatment.